Stock Taper 
VCRE
$10.35
▼ DOWN 0.48% (-0.05)
KEY STATISTICS
Market Cap$2.91 B
52w High$17.80
52w Low$10.03
Dividend Yield—
Frequency—
P/E—
Volume27.09K
Shares Out.281.53M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Ahmed Mousa
ABOUT
SECTOR
Healthcare
WENT PUBLIC
July 2, 2026
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
37
UPCOMING EARNINGS
DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU
PRICE
$10.35 ▼ DOWN 0.48% (−$0.05)About Vicore Pharma Holding AB
https://vicorepharma.com ↗Vicore Pharma Holding AB, founded in 2000 and based in Stockholm, Sweden, develops drugs for interstitial lung diseases, including programs VP01 to VP04.
INDUSTRY
Biotechnology
A PRODUCT VICORE PHARMA HOLDING AB IS KNOWN FOR
Buloxibutid (C21)
Buloxibutid, Vicore Pharma’s lead oral drug candidate for IPF and fibrotic diseases, is in Phase 2b trials with FDA Fast Track and Orphan Drug designations, aiming to address a critical unmet medical need.
RATINGS SNAPSHOT
Overall rating: C-
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1